<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>News | GeyikLab</title>
    <meta name="description" content="News archive, project acceptances, and updates from GeyikLab.">
    
    <!-- Typography -->
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link href="https://fonts.googleapis.com/css2?family=Merriweather:wght@300;700;900&family=Open+Sans:wght@400;600&display=swap" rel="stylesheet">

    <style>
        /* =========================================
           1. VARIABLES & THEME (MATCHING OTHER PAGES)
           ========================================= */
        :root {
            --primary: #0f172a;    
            --secondary: #334155;  
            --accent: #0284c7;     
            --bg-hero: #f8fafc;    
            --white: #ffffff;
            --border: #e2e8f0;
            --max-width: 1250px;   /* Standard Site Width */
            --read-width: 850px;   /* Narrower width for reading text */
            --shadow: 0 4px 6px -1px rgba(0, 0, 0, 0.1);
        }

        /* =========================================
           2. GLOBAL RESET 
           ========================================= */
        * { box-sizing: border-box; margin: 0; padding: 0; }
        
        html {
            scroll-padding-top: 100px; 
            scroll-behavior: smooth;
        }

        body {
            font-family: 'Open Sans', sans-serif;
            color: var(--secondary);
            line-height: 1.7;
            background-color: var(--white);
            display: flex;
            flex-direction: column;
            min-height: 100vh;
        }

        h1, h2, h3, h4 { 
            font-family: 'Merriweather', serif; 
            color: var(--primary); 
            line-height: 1.3; 
            font-weight: 700; 
        }
        
        a { text-decoration: none; color: inherit; transition: all 0.2s; }

        /* =========================================
           3. HEADER (MATCHING RESEARCH/MEMBERS)
           ========================================= */
        header {
            background: var(--white);
            border-bottom: 1px solid var(--border);
            position: sticky; top: 0; z-index: 1000; padding: 0.5rem 0;
        }

        /* Match the 1250px width of other headers */
        .container { max-width: var(--max-width); margin: 0 auto; padding: 0 2.5rem; }

        .nav-wrapper { display: flex; justify-content: space-between; align-items: center; height: 70px; }

        .logo { font-family: 'Merriweather', serif; font-weight: 900; font-size: 1.6rem; color: var(--primary); }
        .logo span { color: var(--accent); }

        nav ul { display: flex; gap: 2.5rem; list-style: none; }
        
        nav a {
            font-weight: 600; font-size: 0.95rem; color: var(--secondary);
            padding: 0.5rem 0; border-bottom: 2px solid transparent;
        }

        nav a:hover, nav a.active { color: var(--accent); border-bottom-color: var(--accent); }

        /* =========================================
           4. PAGE LAYOUT & HERO 
           ========================================= */
        .page-header {
            background-color: var(--bg-hero);
            padding: 4rem 0;
            border-bottom: 1px solid var(--border);
            margin-bottom: 4rem; 
        }
        .page-header h1 { font-size: 2.5rem; font-weight: 900; }

        /* Reading Container (Narrower than full width) */
        .container-read {
            max-width: var(--read-width);
            margin: 0 auto;
            padding: 0 2.5rem;
            margin-bottom: 4rem;
        }

        /* =========================================
           5. NEWS FEED STYLES
           ========================================= */
        
        /* Timeline Container */
        .news-feed {
            position: relative;
            padding-left: 2rem; 
            border-left: 2px solid var(--border); 
            margin-top: 2rem;
        }

        /* News Card */
        .news-card {
            background: var(--white);
            margin-bottom: 4rem;
            position: relative;
        }

        /* The Timeline Dot */
        .news-card::before {
            content: '';
            position: absolute;
            left: -2.6rem; /* Adjust based on padding-left of parent */
            top: 0.4rem;
            width: 16px; height: 16px;
            background: var(--white);
            border: 4px solid var(--accent);
            border-radius: 50%;
            box-shadow: 0 0 0 4px var(--white); /* White ring for separation */
        }

        /* Meta Data (Date & Tag) */
        .news-meta {
            display: flex;
            align-items: center;
            gap: 1rem;
            margin-bottom: 0.8rem;
            font-size: 0.85rem;
        }

        .news-date {
            color: #94a3b8;
            font-weight: 700;
            text-transform: uppercase;
            letter-spacing: 1px;
        }

        .news-tag {
            background-color: #e0f2fe;
            color: var(--accent);
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            font-size: 0.75rem;
            text-transform: uppercase;
        }

        /* Content */
        .news-card h2 { font-size: 1.6rem; margin-bottom: 1rem; line-height: 1.3; }
        .news-card p { margin-bottom: 1rem; font-size: 1.05rem; }
        
        .news-card strong { color: var(--primary); }
        .news-card em { color: var(--secondary); font-style: italic; }

        /* =========================================
           6. FOOTER 
           ========================================= */
        footer {
            margin-top: auto; background: var(--primary); color: #cbd5e1;
            padding: 3rem 0; text-align: center; font-size: 0.9rem;
        }

        /* Mobile */
        @media (max-width: 850px) {
            .nav-wrapper { flex-direction: column; height: auto; padding: 1rem 0; }
            nav ul { margin-top: 1rem; gap: 1rem; flex-wrap: wrap; justify-content: center; }
            
            .news-feed { padding-left: 1.5rem; }
            .news-card::before { left: -2.1rem; width: 14px; height: 14px; }
        }
    </style>
</head>
<body>

    <!-- HEADER -->
    <header>
        <div class="container nav-wrapper">
            <a href="index.html" class="logo">Geyik<span>Lab</span></a>
            <nav>
                <ul>
                    <li><a href="index.html">Home</a></li>
                    <li><a href="research.html">Research</a></li>
                    <li><a href="members.html">Members</a></li>
                    <li><a href="news.html" class="active">News</a></li>
                    <li><a href="contact.html">Contact</a></li>
                </ul>
            </nav>
        </div>
    </header>

    <!-- PAGE TITLE -->
    <section class="page-header">
        <div class="container">
            <h1>Lab News</h1>
            <p style="color: #64748b; margin-top: 0.5rem; font-size: 1.1rem;">
                Updates, grant acceptances, and conference presentations.
            </p>
        </div>
    </section>

    <!-- MAIN CONTENT -->
    <main class="container-read">
        <div class="news-feed">
            
            <!-- News Item 1 -->
            <article class="news-card">
                <div class="news-meta">
                    <span class="news-date">December 24, 2025</span>
                    <span class="news-tag">Lab Update</span>
                </div>
                <h2>New COST Working Group Membership</h2>
                <p>
                    Dr. Geyik now participates as a member of "Working Group 1: Genetic and epigenetic mechanisms" in <strong>CA24162 - Adaptive and acquired resistance in gastrointestinal cancers-contemporary and emerging resolutions (AdResCanCER)</strong>.
                </p>
                <p>
                    This new collaboration is already shaping our research directions: the thesis subjects of our PhD candidates directly aligned with the scientific goals of this Action, fostering greater international integration for their work!
                </p>
            </article>
            
            <!-- News Item 2 -->
            <article class="news-card" id="slide2">
                <div class="news-meta">
                    <span class="news-date">December 23, 2025</span>
                    <span class="news-tag">Lab Update</span>
                </div>
                <h2>New Team Member!</h2>
                <p>
                    GeyikLab is pleased to announce that Çisem ÖZGÜNGÖR has joined our research group!
                </p>
                <p>
                    She is currently completing her coursework in the Cancer Biology and Pharmacology program. We are excited to have her on board and look forward to the fresh perspectives she will bring to the lab as she develops her research focus.
                </p>
            </article>
            
            <!-- News Item 3 -->
            <article class="news-card">
                <div class="news-meta">
                    <span class="news-date">December 10, 2025</span>
                    <span class="news-tag">Lab Update</span>
                </div>
                <h2>New COST Working Group Membership</h2>
                <p>
                    Dr. Geyik now participates as a member of "Working Group 2: Preclinical" in <strong>CA24130 - Psychedelic renaissance: turn on, tune in and drop in (PSY-NET)</strong>.
                </p>
                <p>
                    Stay tuned for further news on the subject!
                </p>
            </article>
            
            <!-- News Item 4 -->
            <article class="news-card" id="slide3">
                <div class="news-meta">
                    <span class="news-date">November 24, 2025</span>
                    <span class="news-tag">Project</span>
                </div>
                <h2>TUBITAK Project Accepted (Collaboration)</h2>
                <p>
                   We wish to congratulate our collaborator, Dr. Berrak VARAN, for their new project funded by TUBITAK 1002 program.
                </p>
                <p>
                    In this project, we will investigate varying levels of Nf-L in different exercise groups in Multiple Sclerosis patients.
                </p>
            </article>
     
            <!-- News Item 5 -->
            <article class="news-card" id="project-acceptance2">
                <div class="news-meta">
                    <span class="news-date">February 27, 2025</span>
                    <span class="news-tag">Project</span>
                </div>
                <h2>TUBITAK Project Accepted</h2>
                <p>
                    We are happy to announce that our project proposal titled <em>"Effect of CLOCK Inhibition on Temozolomide Response in Glioblastoma Cells" (Glioblastoma Hücrelerinde CLOCK İnhibisyonunun Temozolomid Yanıtına Etkisi)</em> has been accepted for funding by TUBITAK 1002/A.
                </p>
                <p>
                    In this project, circadian clock regulation in chemotherapy will be modeled in glioblastoma cell lines.
                </p>
            </article>
            
            <!-- News Item 6 -->
            <article class="news-card">
                <div class="news-meta">
                    <span class="news-date">May 27, 2024</span>
                    <span class="news-tag">Project</span>
                </div>
                <h2>TUSEB Project Accepted (Collaboration)</h2>
                <p>
                  We wish to congratulate Dr. Öykü GÖNÜL GEYİK for her new project funded by the TUSEB A program. For those who don't know, Dr. Gönül Geyik holds a unique dual title: she is a key scientific collaborator on this website, and also the wife of Dr. Geyik. While she manages this new research project, she also manages me, which is arguably the harder job. We are so proud of you, Öykü!
                </p>
                <p>
                    In this project, ferroptosis induced by artesunate will be investigated in cholangiocarcinoma cells.
                </p>
            </article>
            
            <!-- News Item 7 -->
            <article class="news-card">
                <div class="news-meta">
                    <span class="news-date">April 15, 2022</span>
                    <span class="news-tag">Project</span>
                </div>
                <h2>TUSEB Project Accepted</h2>
                <p>
                    We are happy to announce that our project proposal titled <em>"The Effect of KRAS Mutation and Nrf2 Inhibition on Irinotecan Treatment in Colorectal Cancer" (Kolorektal Kanserde KRAS Mutasyonu ve Nrf2 İnhibisyonunun İrinotekan Tedavisine Etkisi)</em> has been accepted for funding by TUSEB A (2022-ACİL-08).
                </p>
                <p>
                    This project will allow us to investigate the combinatory effects of using NRF2 inhibitors and chemotherapeutic agents in KRAS-mutant colorectal cancers.
                </p>
            </article>

        </div>
    </main>

    <footer>
        <div class="container">
            <p>&copy; 2025 GeyikLab. All rights reserved.</p>
        </div>
    </footer>

</body>
</html>
